5-MAPDB

5-MAPDB
Clinical data
Other names	5-(2-(Methylamino)propyl)-2,3-dihydrobenzofuran; 1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine
Legal status
Legal status	AU: Analogue of MDMA; BR: Class F2 (Prohibited psychotropics); CA: Schedule I; DE: NpSG (Industrial and scientific use only); UK: Class B; US: Analogue to a Schedule I/II drug (MDMA);
Identifiers
	IUPAC name 1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine;
CAS Number	1354631-78-9;
PubChem CID	112500533;
ChemSpider	52085108;
UNII	FS5Z21939Z;
CompTox Dashboard (EPA)	DTXSID601045392 ;
Chemical and physical data
Formula	C12H17NO
Molar mass	191.274 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(NC)CC1=CC(CCO2)=C2C=C1;
	InChI InChI=1S/C12H17NO/c1-9(13-2)7-10-3-4-12-11(8-10)5-6-14-12/h3-4,8-9,13H,5-7H2,1-2H3; Key:PLQTZOCLUHHCOI-UHFFFAOYSA-N;

5-MAPDB, also known as 5-(2-(methylamino)propyl)-2,3-dihydrobenzofuran, is an entactogen of the dihydrobenzofuran family. It is structurally related to drugs like 5-APDB and 5-MAPB, which have similar effects to MDMA and have been used as recreational drugs. 5-MAPDB has been studied to determine its pharmacological activity, and was found to be a relatively selective serotonin releaser, though with weaker actions as a releaser of other monoamines and 5-HT₂ receptor family agonist, similar to older compounds such as 5-APDB.